Next Generation Sequencer

下一代测序仪

• 批准号: 7791131
• 负责人: Charis Eng
• 金额: $ 50万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-11 至 2011-03-10
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7791131
• 关键词: Applications Grants; Biological Markers; Clinic; Clinical; Commit; Core Facility; DNA; DNA-Protein Interaction; Detection; Development; Ensure; Epigenetic Process; Functional RNA; Funding; Gene Expression Profiling; Generations; Genome; Genomics; Human Resources; Institute of Medicine (U.S.); Institution; Lifting; Maintenance; Marketing; Medicine; Ohio; Patients; Regulation; Research; Research Project Grants; Resources; Running; Technology; Transcript; Translational Research; United States National Institutes of Health; Work; base; digital; disease-causing mutation; flexibility; genome sequencing; genome-wide; human disease; instrument; instrumentation; next generation; operation; programs

DESCRIPTION (provided by applicant): The proposed work in this shared instrumentation grant application comes from many of the clinical and/or translational research programs ongoing at the Cleveland Clinic, a major research institution in the northeast Ohio region. The purpose of this application is to seek funding to purchase a next generation sequencer, the Illumina Genome Analyzer IIx. All but one of the major users is NIH/NCI funded by a variety of mechanisms (R01, P01, U54, etc). The Genome Analyzer has the power and flexibility to enable a wide range of genome-scale applications. The instrument is a direct consequence of the NIH initiative for the $1000 genome and represents the first generation of such technologies to come to the market. The underlying technology can be summarized as massive parallel sequencing (creating 2-4 GB of sequence in a typical 3-5 day run). As detailed in the application, the supported projects primarily include biomarker discovery and clinical/translational sciences studies, representing the unique strengths in our institution and taking advantage of all current applications of the next generation sequencers: 1) digital gene expression profiling: better dynamic range than micro-array based profiling and reliable detection of low-abundance transcripts, 2) ChIP-seq: genome wide profiles of DNA-protein interaction and of epigenetic regulation in translational research programs related to human disease, 3) small or non-coding RNA discovery and 4) genome sequencing: re- sequencing of large genomic regions in patient DNA to uncover disease causing mutations. The acquisition of the Genome Analyzer, with its scale and value, are essential in lifting the currently NIH-funded projects and many other new projects to the next higher level of translational sciences in northeast Ohio. Cleveland Clinic has already committed substantial resources to the development of translational genomics and genomic medicine, including the founding of its Genomic Medicine Institute with a new Genomics Core Facility, personnel to oversee operations and a fiscal plan to ensure its operation and maintenance for the long-term.

描述（由申请人提供）：此共享仪器拨款申请中拟议的工作来自克利夫兰诊所正在进行的许多临床和/或转化研究项目，克利夫兰诊所是俄亥俄州东北部地区的一家主要研究机构。此申请的目的是寻求资金购买下一代测序仪 Illumina Genome Analyzer IIx。除其中一个主要用户外，所有其他用户都是由各种机制（R01、P01、U54 等）资助的 NIH/NCI。基因组分析仪具有强大的功能和灵活性，可实现广泛的基因组规模应用。该仪器是 NIH 1000 美元基因组计划的直接成果，代表了进入市场的第一代此类技术。底层技术可以概括为大规模并行测序（在典型的 3-5 天运行中创建 2-4 GB 的序列）。正如申请中详细说明的，支持的项目主要包括生物标志物发现和临床/转化科学研究，代表了我们机构的独特优势，并利用了下一代测序仪的所有当前应用：1) 数字基因表达谱分析：比基于微阵列的分析更好的动态范围和低丰度转录本的可靠检测，2) ChIP-seq：DNA-蛋白质相互作用的全基因组谱和 与人类疾病相关的转化研究项目中的表观遗传调控，3) 小或非编码 RNA 发现，4) 基因组测序：对患者 DNA 中的大基因组区域进行重新测序，以发现引起疾病的突变。基因组分析仪的收购，以其规模和价值，对于将当前 NIH 资助的项目和许多其他新项目提升到俄亥俄州东北部转化科学的下一个更高水平至关重要。克利夫兰诊所已经投入了大量资源来发展转化基因组学和基因组医学，包括建立基因组医学研究所，拥有新的基因组学核心设施、监督运营的人员以及确保其长期运营和维护的财务计划。